Glaxo And Theravance Launch Phase III Study For Fluticasone Furoate/Vilanterol
LONDON (Alliance News) - GlaxoSmithKline PLC said Tuesday that, along with Theravance Inc, it will be launching a phase III study for the combination treatment of fluticasone furoate/vilanterol for chronic obstructive pulmonary disease. Glaxo said that positive results from the study would Read More